ELDECORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ELDECORT (ELDECORT).
Corticosteroid binding to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of prostaglandins and leukotrienes, and modulation of cytokine production.
| Metabolism | Primarily hepatic via CYP3A4; also metabolized by other CYP450 enzymes; undergoes reduction and conjugation; small amount reduced to prednisolone. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination contributes about 30% due to biliary secretion; the remaining 10% is metabolized. |
| Half-life | Terminal elimination half-life is 3.5 ± 1.2 hours in adults with normal renal function; prolonged to 6–8 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 92% bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | 0.20–0.25 L/kg, indicating moderate distribution into total body water; lower in obese patients (0.15 L/kg). |
| Bioavailability | Oral: 85–90%; intramuscular: 100%; intravenous: 100%. |
| Onset of Action | Intravenous: within 5 minutes; oral: 30–60 minutes; intramuscular: 15–30 minutes. |
| Duration of Action | Intravenous: 4–6 hours; oral: 6–8 hours; intramuscular: 8–12 hours; duration is dose-dependent and extended in hepatic impairment. |
Initial: 5-60 mg orally once daily, adjusted based on response; typical maintenance: 5-15 mg orally once daily.
| Dosage form | CREAM |
| Renal impairment | No specific dose adjustment required for renal impairment; monitor for fluid retention and hypertension. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50%. Child-Pugh Class C: Avoid use or reduce dose by 75% with close monitoring. |
| Pediatric use | 0.1-2 mg/kg/day orally in divided doses every 6-12 hours; maximum 60 mg/day. |
| Geriatric use | Start at lowest effective dose (e.g., 2.5-5 mg/day); monitor for osteoporosis, hyperglycemia, and immunosuppression. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ELDECORT (ELDECORT).
| Breastfeeding | Enters breast milk; M/P ratio approximately 0.1-0.4. Low concentrations; considered compatible with breastfeeding but monitor for potential adrenal suppression in high doses or prolonged use. |
| Teratogenic Risk | First trimester: Increased risk of orofacial clefts (odds ratio 1.3-3.4). Second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, oligohydramnios. Chronic use: Premature closure of ductus arteriosus, persistent pulmonary hypertension. |
| Fetal Monitoring |
■ FDA Black Box Warning
May increase risk of opportunistic infections, including reactivation of latent tuberculosis and fungal infections. Avoid live vaccines during therapy. Corticosteroids can cause adrenal suppression upon withdrawal.
| Serious Effects |
Systemic fungal infections; hypersensitivity to any component; administration of live or live-attenuated vaccines; idiopathic thrombocytopenic purpura (IM use); peptic ulcer disease; osteomalacia; recent intestinal anastomosis; active tuberculosis.
| Precautions | Adrenal suppression during stress or withdrawal; increased susceptibility to infections; masking of infection signs; gastrointestinal perforation; osteoporosis; ocular effects (cataracts, glaucoma); growth suppression in children; psychiatric disturbances; thromboembolic events; hypercorticism; potassium wasting. |
Loading safety data…
| Maternal: Blood pressure, blood glucose, weight gain, signs of infection. Fetal: Serial ultrasound for growth, amniotic fluid index, ductus arteriosus Doppler if used >2 weeks after 20 weeks. |
| Fertility Effects | May inhibit ovulation at high doses via suppression of hypothalamic-pituitary-ovarian axis; reversible upon discontinuation. |